About US
Contact us
-
UPDATED: FDA to look again at reclassifying hydrocodone combosCombination pain drugs like Vicodin from Abbott Laboratories ($ABT) are a pain for the Drug Enforcement Administration because they are easy to get and often abused. The DEA has again asked the FDA t2012/6/11
-
Pfizer readies documents for animal health IPOPfizer ($PFE) is prepping registration documents for an animal-health IPO. The company would offer a minority stake in the unit, dubbed Zoetis, as a step toward spinning off the unit completely. It's2012/6/8
-
Pharma feeds multiply on TwitterPharma may not be the most Twitter-savvy industry. But drugmakers have more toes in the Twitterverse than ever: According to Eye on FDA, at least 44 pharma companies have a Twitter feed, and altogethe2012/6/8
-
Study finds Roche's Actemra bests Abbott's blockbuster HumiraSwiss drug giant Roche ($RHHBY) today released data from a Phase IV study at the European League Against Rheumatism's annual conference in Berlin that showed its treatment Actemra--marketed in Euro2012/6/7
-
House would cut $16 million from FDA fundingA House appropriations proposal provides less FDA funding than the Senate or White House suggested and shaves $16.3 million off the current year's total, a comparison by an FDA support group shows.2012/6/7
-
Some drug recalls slip through FDA-reporting cracksThe FDA needs a new recall-alert system, researchers say. That's because some drug recalls--even the most serious, Class I type--haven't been adequately aired. "[W]e anticipate that a lot of provid2012/6/6
-
Reports: Pfizer to cut 180 jobs at two Irish plantsAfter Irish media reported 180 impending job cuts at Pfizer ($PFE) manufacturing plants in Cork, the company called employee meetings for tomorrow at both facilities for an official update. Local news2012/6/6
-
Roche's Zelboraf targeted by GSK melanoma drugsRoche ($RHHBY) may have to circle the wagons around its targeted melanoma drug Zelboraf. Positive data on two GlaxoSmithKline ($GSK) melanoma treatments have analysts predicting a quick assault on mar2012/6/5
-
ASCO: Data on J&J, Medivation meds spell trouble for ProvengeAfter last year's debut of Dendreon's ($DNDN)immunotherapy Provenge and Johnson & Johnson's ($JNJ)pill Zytiga, prostate cancer treatment may be in for another big shake-up. At the American Soci2012/6/5
-
New AstraZeneca chairman looks for CEOAstraZeneca($AZN) is on the hunt for a replacement for ex-CEO David Brennan.Leif Johansson, who takes over as chairman today, tells The Financial Times that finding the right leader is his first prior2012/6/4